These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

238 related items for PubMed ID: 8388200

  • 21. Expression in Escherichia coli of Y5-mutant and N-terminal domain-deleted DNA gyrase B proteins affects strongly plasmid maintenance.
    Brino L, Mousli M, Oudet P, Weiss E.
    Plasmid; 1997; 38(3):188-201. PubMed ID: 9435021
    [Abstract] [Full Text] [Related]

  • 22. Alteration of bacterial DNA structure, gene expression, and plasmid encoded antibiotic resistance following exposure to enoxacin.
    Courtright JB, Turowski DA, Sonstein SA.
    J Antimicrob Chemother; 1988 Feb; 21 Suppl B():1-18. PubMed ID: 2834313
    [Abstract] [Full Text] [Related]

  • 23. Quinolone-binding pocket of DNA gyrase: role of GyrB.
    Heddle J, Maxwell A.
    Antimicrob Agents Chemother; 2002 Jun; 46(6):1805-15. PubMed ID: 12019094
    [Abstract] [Full Text] [Related]

  • 24. Role of the extended alpha4 domain of Staphylococcus aureus gyrase A protein in determining low sensitivity to quinolones.
    Strahilevitz J, Robicsek A, Hooper DC.
    Antimicrob Agents Chemother; 2006 Feb; 50(2):600-6. PubMed ID: 16436716
    [Abstract] [Full Text] [Related]

  • 25. Novel gyrase mutations in quinolone-resistant and -hypersusceptible clinical isolates of Mycobacterium tuberculosis: functional analysis of mutant enzymes.
    Aubry A, Veziris N, Cambau E, Truffot-Pernot C, Jarlier V, Fisher LM.
    Antimicrob Agents Chemother; 2006 Jan; 50(1):104-12. PubMed ID: 16377674
    [Abstract] [Full Text] [Related]

  • 26. Mutations in topoisomerase IV and DNA gyrase of Staphylococcus aureus: novel pleiotropic effects on quinolone and coumarin activity.
    Fournier B, Hooper DC.
    Antimicrob Agents Chemother; 1998 Jan; 42(1):121-8. PubMed ID: 9449271
    [Abstract] [Full Text] [Related]

  • 27. Interaction of the plasmid-encoded quinolone resistance protein Qnr with Escherichia coli DNA gyrase.
    Tran JH, Jacoby GA, Hooper DC.
    Antimicrob Agents Chemother; 2005 Jan; 49(1):118-25. PubMed ID: 15616284
    [Abstract] [Full Text] [Related]

  • 28. Mode of action of the new quinolones: new data.
    Hooper DC, Wolfson JS.
    Eur J Clin Microbiol Infect Dis; 1991 Apr; 10(4):223-31. PubMed ID: 1650698
    [Abstract] [Full Text] [Related]

  • 29. Novel quinolone resistance mutations of the Escherichia coli DNA gyrase A protein: enzymatic analysis of the mutant proteins.
    Hallett P, Maxwell A.
    Antimicrob Agents Chemother; 1991 Feb; 35(2):335-40. PubMed ID: 1850970
    [Abstract] [Full Text] [Related]

  • 30. Functions of a GyrBA fusion protein and its interaction with QnrB and quinolones.
    Chen C, Villet R, Jacoby GA, Hooper DC.
    Antimicrob Agents Chemother; 2015 Nov; 59(11):7124-7. PubMed ID: 26324265
    [Abstract] [Full Text] [Related]

  • 31. Fluoroquinolones inhibit preferentially Streptococcus pneumoniae DNA topoisomerase IV than DNA gyrase native proteins.
    Fernandez-Moreira E, Balas D, Gonzalez I, de la Campa AG.
    Microb Drug Resist; 2000 Nov; 6(4):259-67. PubMed ID: 11272253
    [Abstract] [Full Text] [Related]

  • 32. Activities of trovafloxacin compared with those of other fluoroquinolones against purified topoisomerases and gyrA and grlA mutants of Staphylococcus aureus.
    Gootz TD, Zaniewski RP, Haskell SL, Kaczmarek FS, Maurice AE.
    Antimicrob Agents Chemother; 1999 Aug; 43(8):1845-55. PubMed ID: 10428901
    [Abstract] [Full Text] [Related]

  • 33. Cleavable-complex formation by wild-type and quinolone-resistant Streptococcus pneumoniae type II topoisomerases mediated by gemifloxacin and other fluoroquinolones.
    Yague G, Morris JE, Pan XS, Gould KA, Fisher LM.
    Antimicrob Agents Chemother; 2002 Feb; 46(2):413-9. PubMed ID: 11796351
    [Abstract] [Full Text] [Related]

  • 34. Mechanism of differential activities of ofloxacin enantiomers.
    Morrissey I, Hoshino K, Sato K, Yoshida A, Hayakawa I, Bures MG, Shen LL.
    Antimicrob Agents Chemother; 1996 Aug; 40(8):1775-84. PubMed ID: 8843280
    [Abstract] [Full Text] [Related]

  • 35. A mutation in yeast TOP2 homologous to a quinolone-resistant mutation in bacteria. Mutation of the amino acid homologous to Ser83 of Escherichia coli gyrA alters sensitivity to eukaryotic topoisomerase inhibitors.
    Hsiung Y, Elsea SH, Osheroff N, Nitiss JL.
    J Biol Chem; 1995 Sep 01; 270(35):20359-64. PubMed ID: 7657608
    [Abstract] [Full Text] [Related]

  • 36. Contribution of the C-8 substituent of DU-6859a, a new potent fluoroquinolone, to its activity against DNA gyrase mutants of Pseudomonas aeruginosa.
    Kitamura A, Hoshino K, Kimura Y, Hayakawa I, Sato K.
    Antimicrob Agents Chemother; 1995 Jul 01; 39(7):1467-71. PubMed ID: 7492087
    [Abstract] [Full Text] [Related]

  • 37. Molecular cloning of the gyrA and gyrB genes of Bacteroides fragilis encoding DNA gyrase.
    Onodera Y, Sato K.
    Antimicrob Agents Chemother; 1999 Oct 01; 43(10):2423-9. PubMed ID: 10508019
    [Abstract] [Full Text] [Related]

  • 38. Quinolone action in Escherichia coli cells carrying gyrA and gyrB mutations.
    Herrera G, Aleixandra V, Urios A, Blanco M.
    FEMS Microbiol Lett; 1993 Jan 15; 106(2):187-91. PubMed ID: 8384139
    [Abstract] [Full Text] [Related]

  • 39. Mutations in the gyrA gene of a highly fluoroquinolone-resistant clinical isolate of Escherichia coli.
    Heisig P, Schedletzky H, Falkenstein-Paul H.
    Antimicrob Agents Chemother; 1993 Apr 15; 37(4):696-701. PubMed ID: 8388197
    [Abstract] [Full Text] [Related]

  • 40. A comparison of active site binding of 4-quinolones and novel flavone gyrase inhibitors to DNA gyrase.
    Hilliard JJ, Krause HM, Bernstein JI, Fernandez JA, Nguyen V, Ohemeng KA, Barrett JF.
    Adv Exp Med Biol; 1995 Apr 15; 390():59-69. PubMed ID: 8718602
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.